Tag #Drug Shortages

Showing 13 to 18 of 18 results

es.euronews.com

🌐 85% Global Worthiness

Mar 11, 22:12

EU Proposes New Law to Tackle Medicine Shortages

The EU proposed a new Essential Medicines Act, including a mechanism prioritizing EU-produced medicines in public contracts to address medicine shortages, particularly antibiotics, insulin, and analgesics, by boosting domestic production and coordinated purchasing for scarce drugs, although concerns...

EU Proposes New Law to Tackle Medicine Shortages

The EU proposed a new Essential Medicines Act, including a mechanism prioritizing EU-produced medicines in public contracts to address medicine shortages, particularly antibiotics, insulin, and analgesics, by boosting domestic production and coordinated purchasing for scarce drugs, although concerns...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What measures are proposed to address critical medicine shortages in the EU, and what are the immediate implications for patient access?

The European Union proposed a new law to address medicine shortages, introducing a mechanism prioritizing EU-made pharmaceuticals in public contracts when supply chain vulnerabilities exist. This aims to reduce reliance on foreign suppliers and ensure access to essential medicines like antibiotics and insulin, a concern heightened by the COVID-19 pandemic.

tr.euronews.com

🌐 85% Global Worthiness

Feb 28, 22:09

Pharmaceutical Firms Oppose EU's Rushed Medicine Shortage Act

The European Commission's proposed Critical Medicines Act, aiming to prevent medicine shortages in the EU by March 11th, faces opposition from major pharmaceutical companies like Roche and Bayer due to concerns over insufficient impact assessment and rushed preparation, prompting calls for a more th...

Pharmaceutical Firms Oppose EU's Rushed Medicine Shortage Act

The European Commission's proposed Critical Medicines Act, aiming to prevent medicine shortages in the EU by March 11th, faces opposition from major pharmaceutical companies like Roche and Bayer due to concerns over insufficient impact assessment and rushed preparation, prompting calls for a more th...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the main arguments raised by pharmaceutical companies against the Critical Medicines Act, and how do these concerns relate to the Commission's stated goals?

Pharmaceutical companies argue the Critical Medicines Act lacks thorough analysis of its consequences, particularly for small and medium-sized enterprises. Groups like EUCOPE and EFPIA echo these concerns, emphasizing the need for a comprehensive impact assessment before implementation. This highlights a conflict between the Commission's urgency to address medicine shortages and the industry's call for more careful consideration.

cnbc.com

🌐 75% Global Worthiness

Jan 3, 01:07

Lilly Intervenes in Lawsuit over Compounded Tirzepatide Drugs

Eli Lilly joined a lawsuit against the FDA, contesting the agency's October 2023 decision ending the shortage designation for its tirzepatide-based drugs (Zepbound and Mounjaro), impacting the legality of cheaper compounded alternatives. The FDA affirmed its decision in December, but the compounding...

Lilly Intervenes in Lawsuit over Compounded Tirzepatide Drugs

Eli Lilly joined a lawsuit against the FDA, contesting the agency's October 2023 decision ending the shortage designation for its tirzepatide-based drugs (Zepbound and Mounjaro), impacting the legality of cheaper compounded alternatives. The FDA affirmed its decision in December, but the compounding...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the FDA's decision on tirzepatide drug shortages affect the operations and profitability of compounding pharmacies?

This legal dispute centers on the FDA's October 2023 decision that tirzepatide drugs are not in short supply, thereby restricting compounding pharmacies' ability to produce lower-cost alternatives. Lilly's intervention underscores the conflict between the FDA's regulatory stance, the financial implications for Lilly, and the access to affordable medications for patients. The case outcome will determine the future availability and pricing of compounded tirzepatide drugs.

forbes.com

🌐 90% Global Worthiness

Mar 4, 22:09

US Tariffs on Pharmaceuticals: Expected Price Increases and Shortages

The Trump administration levied tariffs on China, Mexico, and Canada, ostensibly targeting fentanyl but impacting the U.S. pharmaceutical supply chain, causing predicted drug price increases of at least 10%, and potentially exacerbating existing drug shortages due to 80% of drug ingredients being so...

US Tariffs on Pharmaceuticals: Expected Price Increases and Shortages

The Trump administration levied tariffs on China, Mexico, and Canada, ostensibly targeting fentanyl but impacting the U.S. pharmaceutical supply chain, causing predicted drug price increases of at least 10%, and potentially exacerbating existing drug shortages due to 80% of drug ingredients being so...

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of the Trump administration's tariffs on the U.S. pharmaceutical supply chain and consumers?

The Trump administration imposed tariffs on China, Mexico, and Canada, citing fentanyl concerns, not trade. This impacts the already globalized US pharmaceutical supply chain, where 80% of drug ingredients are sourced overseas, with 13% of active pharmaceutical ingredients (APIs) from China alone. Price increases are expected, with seven in ten experts predicting at least a 10% rise in drug costs.

lentreprise.lexpress.fr

🌐 85% Global Worthiness

Jan 26, 01:05

Europe's Slow Progress Towards Pharmaceutical Sovereignty

Europe's pharmaceutical supply chain is vulnerable due to reliance on distant countries for raw materials and production; this has led to shortages of essential medicines, prompting calls for higher drug prices and increased domestic production.

Europe's Slow Progress Towards Pharmaceutical Sovereignty

Europe's pharmaceutical supply chain is vulnerable due to reliance on distant countries for raw materials and production; this has led to shortages of essential medicines, prompting calls for higher drug prices and increased domestic production.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key factors contributing to Europe's pharmaceutical supply chain vulnerabilities, and what are the immediate consequences?

Europe's efforts to regain pharmaceutical sovereignty are slow, with many medications still in short supply due to reliance on distant countries for raw materials and production. This model, prioritizing low costs, led to 80% of essential active ingredients originating from India or China, a significant increase from 20% two decades ago.

lexpress.fr

🌐 85% Global Worthiness

Dec 27, 10:07

Europe's Pharmaceutical Dependence: Challenges and Solutions

Europe's pharmaceutical sovereignty is hampered by its reliance on India and China for 80% of essential drug ingredients, a consequence of cost-cutting measures that have led to production shifts and drug shortages. France, once the leading producer, is now fourth.

Europe's Pharmaceutical Dependence: Challenges and Solutions

Europe's pharmaceutical sovereignty is hampered by its reliance on India and China for 80% of essential drug ingredients, a consequence of cost-cutting measures that have led to production shifts and drug shortages. France, once the leading producer, is now fourth.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the most significant challenges hindering Europe's efforts to achieve pharmaceutical sovereignty?

Europe's pursuit of pharmaceutical sovereignty faces significant hurdles. 80% of essential drug ingredients originate from India or China, up from 20% two decades ago, highlighting a heavy reliance on foreign suppliers. This dependence, exacerbated by cost-cutting measures and globalized production, has led to drug shortages and vulnerabilities.

Showing 13 to 18 of 18 results